Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 8298503, 14 pages
http://dx.doi.org/10.1155/2016/8298503
Clinical Study

Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease

1Lighthouse Guild, Arlene R. Gordon Research Institute, New York, NY, USA
2Department of Ophthalmology, NYU School of Medicine, New York, NY, USA
3Institute of Vision, Aging in Vision and Action Lab, CNRS-INSERM, University Pierre & Marie Curie, Paris, France
4Jesse Brown VA Medical Center, Chicago, IL, USA
5Institute for Neurodegenerative Disorders, Suite 8B, 60 Temple Street, New Haven, CT 06510, USA
6New York Eye & Ear Infirmary and Icahn School of Medicine of Mount Sinai, 310 East 14th Street, New York, NY 10003, USA
7Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA

Received 1 July 2016; Revised 6 October 2016; Accepted 31 October 2016

Academic Editor: Hélio Teive

Copyright © 2016 William Seiple et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

William Seiple, Danna Jennings, Richard B. Rosen, et al., “Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease,” Parkinson’s Disease, vol. 2016, Article ID 8298503, 14 pages, 2016. https://doi.org/10.1155/2016/8298503.